Skip to main content
Premium Trial:

Request an Annual Quote

Abbott to Develop Molecular Test for Tarceva in Collaboration with Genentech, Roche, and OSI

NEW YORK (GenomeWeb News) – Illinois-based diagnostics company Abbott has entered into an agreement with Genentech, Roche, and OSI Pharmaceuticals to create a genetic test for determining which lung cancer patients will benefit from erlotinib treatment, the company announced today.
 
Erlotinib, which goes by the trade name Tarceva, is an oral tablet used to treat locally advanced or metastatic non-small cell lung cancer in patients who have tried chemotherapy unsuccessfully. It targets a cell-surface protein called the epidermal growth factor receptor that is often overexpressed in non-small cell lung cancer.
 
Abbott intends to apply its fluorescence in situ hybridization technology to develop a test for extra copies of the gene coding for EGFR. To date, the US Food and Drug Administration has not approved any nucleic acid based tests for predicting successful lung cancer treatment, said Abbott.
 
Financial terms of the agreement were not disclosed.
 

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.